Your browser doesn't support javascript.
loading
Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021.
Mateo-Urdiales, Alberto; Spila Alegiani, Stefania; Fabiani, Massimo; Pezzotti, Patrizio; Filia, Antonietta; Massari, Marco; Riccardo, Flavia; Tallon, Marco; Proietti, Valeria; Del Manso, Martina; Puopolo, Maria; Spuri, Matteo; Morciano, Cristina; D'Ancona, Fortunato Paolo; Da Cas, Roberto; Battilomo, Serena; Bella, Antonino; Menniti-Ippolito, Francesca.
Afiliação
  • Mateo-Urdiales A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Spila Alegiani S; European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Fabiani M; National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Pezzotti P; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Filia A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Massari M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Riccardo F; National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Tallon M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Proietti V; Department of Informatics, Istituto Superiore di Sanità, Rome, Italy.
  • Del Manso M; DG-SISS, Ministero della Salute, Rome, Italy.
  • Puopolo M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Spuri M; European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
  • Morciano C; Department of Neuroscience, Istituto Superiore di Sanità, Rome, Italy.
  • D'Ancona FP; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Da Cas R; Research Coordination and Support Service, Istituto Superiore di Sanità, Rome, Italy.
  • Battilomo S; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Bella A; National Centre for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
  • Menniti-Ippolito F; DG-SISS, Ministero della Salute, Rome, Italy.
Euro Surveill ; 26(25)2021 Jun.
Article em En | MEDLINE | ID: mdl-34169819
ABSTRACT
To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0-14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR) 0.22; 95% CI 0.21-0.24) 43-49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR 0.11; 95% CI 0.09-0.15) and 93% (IRR 0.07; 95% CI 0.04-0.11) reductions 36-42 days post-first dose. Our results support ongoing vaccination campaigns.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Euro Surveill Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas / COVID-19 Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Euro Surveill Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália